CN102038932B - 金属-结合性化合物及其用途 - Google Patents

金属-结合性化合物及其用途 Download PDF

Info

Publication number
CN102038932B
CN102038932B CN2010105807752A CN201010580775A CN102038932B CN 102038932 B CN102038932 B CN 102038932B CN 2010105807752 A CN2010105807752 A CN 2010105807752A CN 201010580775 A CN201010580775 A CN 201010580775A CN 102038932 B CN102038932 B CN 102038932B
Authority
CN
China
Prior art keywords
xaa
peptide
item
metal
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2010105807752A
Other languages
English (en)
Chinese (zh)
Other versions
CN102038932A (zh
Inventor
戴维.巴奥
C.杰拉尔德.柯蒂斯
爱德华.劳
纳加拉加.K.R.拉奥
詹姆斯.V.温克勒
万尼尔.M.克鲁克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
DMI Acquisition Corp
Ampio Pharmaceuticals Inc
Original Assignee
DMI Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26854102&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN102038932(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by DMI Biosciences Inc filed Critical DMI Biosciences Inc
Publication of CN102038932A publication Critical patent/CN102038932A/zh
Application granted granted Critical
Publication of CN102038932B publication Critical patent/CN102038932B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1021—Tetrapeptides with the first amino acid being acidic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/795—Porphyrin- or corrin-ring-containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pyrrole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
CN2010105807752A 1999-10-01 2000-09-29 金属-结合性化合物及其用途 Expired - Fee Related CN102038932B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US15740499P 1999-10-01 1999-10-01
US60/157,404 1999-10-01
US21107800P 2000-06-13 2000-06-13
US60/211,078 2000-06-13

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN00815718A Division CN1390231A (zh) 1999-10-01 2000-09-29 金属－结合性化合物及其用途

Publications (2)

Publication Number Publication Date
CN102038932A CN102038932A (zh) 2011-05-04
CN102038932B true CN102038932B (zh) 2013-11-06

Family

ID=26854102

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2010105807752A Expired - Fee Related CN102038932B (zh) 1999-10-01 2000-09-29 金属-结合性化合物及其用途
CN00815718A Pending CN1390231A (zh) 1999-10-01 2000-09-29 金属－结合性化合物及其用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN00815718A Pending CN1390231A (zh) 1999-10-01 2000-09-29 金属－结合性化合物及其用途

Country Status (11)

Country Link
EP (2) EP2327713A1 (enExample)
JP (1) JP5349722B2 (enExample)
KR (6) KR20100075503A (enExample)
CN (2) CN102038932B (enExample)
AT (1) ATE553116T1 (enExample)
AU (1) AU770999C (enExample)
BR (1) BR0014389A (enExample)
CA (1) CA2385551A1 (enExample)
IL (4) IL148797A0 (enExample)
NZ (1) NZ518266A (enExample)
WO (1) WO2001025265A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030040602A1 (en) * 2001-04-30 2003-02-27 George Jackowski Biopolymer marker indicative of disease state having a molecular weight of 1406 daltons
US20020160417A1 (en) * 2001-04-30 2002-10-31 George Jackowski Biopolymer marker indicative of disease state having a molecular weight of 1424 daltons
AU2002348301B2 (en) * 2001-11-20 2008-05-08 Dmi Biosciences, Inc. Methods and products for oral care
BR0315942A (pt) 2002-11-27 2005-10-04 Dmi Biosciences Inc Tratamento de doenças e condições mediadas pelo aumento de fosforilação
CA2727803C (en) 2008-05-13 2013-03-12 University Of Kansas Metal abstraction peptide (map) tag and associated methods
WO2013181461A2 (en) 2012-06-01 2013-12-05 University Of Kansas Metal abstraction peptide with superoxide dismutase activity
CN111925411B (zh) * 2017-06-29 2022-04-08 安徽省农业科学院农产品加工研究所 一种含有Cys-Ser的高锌螯合活性锌螯合肽及其应用
CN113563418B (zh) * 2021-06-22 2023-03-03 中国科学院化学研究所 一种原位响应ros的人工酶及其制备方法与应用
CN114437175B (zh) * 2022-01-29 2023-09-29 山东第一医科大学第三附属医院(山东省医学科学院附属医院) 一种肽探针及其应用和包含该肽探针的试剂盒

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3941763A (en) 1975-03-28 1976-03-02 American Home Products Corporation PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates
US4022888A (en) 1975-09-09 1977-05-10 Diagnostic Data, Inc. Esterified orgotein
US4461724A (en) 1981-10-28 1984-07-24 Nippon Zoki Pharmaceutical Co., Ltd. Peptide compounds, a process for manufacturing them, pharmaceutical compositions containing them, and methods for treating ulcer and thrombus with them
US4912118A (en) 1983-09-23 1990-03-27 National Research Development Corporation Pharmaceutical compositions
US4760051A (en) 1985-01-24 1988-07-26 Pickart Loren R Use of GHL-Cu as a wound-healing and anti-inflammatory agent
US4877770A (en) 1985-02-08 1989-10-31 Procyte Corporation Chemical derivatives of GHL-Cu
US4665054A (en) 1985-02-08 1987-05-12 Bioheal, Inc. Chemical derivatives of GHL-Cu
US4767753A (en) 1985-02-08 1988-08-30 Procyte Corporation Methods and compositions for preventing ulcers
US5550183A (en) 1985-02-08 1996-08-27 Procyte Corporation Metal-peptide compositions and methods for stimulating hair growth
US5120831A (en) 1985-02-08 1992-06-09 Procyte Corporation Metal-peptide compositions
US4810693A (en) 1985-02-08 1989-03-07 Procyte Corporation Method for inducing biological coverings in wounds
US5177061A (en) 1985-02-08 1993-01-05 Procyte Corporation Method for stimulating hair growth using GHL-Cu complexes
US5348943A (en) 1985-02-08 1994-09-20 Procyte Corporation Cosmetic and skin treatment compositions
US5214032A (en) 1985-02-08 1993-05-25 Procyte Corporation GHL-CU pharmaceutical compositions and compounds
US5422096A (en) 1985-05-08 1995-06-06 The General Hospital Corporation Hydroxy-aryl metal chelates for diagnostic NMR imaging
JPS62116565A (ja) * 1985-11-15 1987-05-28 Fujisawa Pharmaceut Co Ltd 新規ペプチド
GB8603537D0 (en) 1986-02-13 1986-03-19 Parker D Conjugate compound
EP0314755B1 (en) 1987-05-11 1994-08-24 Procyte Corporation Use of derivatives of GHL-Cu for the manufacture of a medicament for stimulating hair growth
ATE110954T1 (de) 1988-01-29 1994-09-15 Peter H Proctor Haarwachstumanregung mit nitroxyd und anderen radikalen.
US5101041A (en) 1989-04-26 1992-03-31 The Curators Of The University Of Missouri Triamines and their derivatives as bifunctional chelating agents
US5443816A (en) 1990-08-08 1995-08-22 Rhomed Incorporated Peptide-metal ion pharmaceutical preparation and method
ATE172879T1 (de) 1989-08-09 1998-11-15 Rhomed Inc Direkte radioetikettierung von antikörpern und sonstigen proteinen mittels technetium oder rhenium
US5460785A (en) 1989-08-09 1995-10-24 Rhomed Incorporated Direct labeling of antibodies and other protein with metal ions
US5759515A (en) 1989-08-09 1998-06-02 Rhomed Incorporated Polyvalent peptide pharmaceutical applications
US5023237A (en) 1989-08-30 1991-06-11 Procyte Corporation Methods and compositions for healing ulcers
US5145838A (en) 1989-08-30 1992-09-08 Procyte Corporation Methods and compositions for healing ulcers
US5059588A (en) 1989-10-13 1991-10-22 Procyte Corporation, Incorporated Methods and compositions for healing bone using gly his lys: copper
US5118665A (en) 1990-02-09 1992-06-02 Procyte Corporation Anti-oxidative and anti-inflammatory metal:peptide complexes and uses thereof
US5164367A (en) 1990-03-26 1992-11-17 Procyte Corporation Method of using copper(ii) containing compounds to accelerate wound healing
US5252559A (en) 1991-08-20 1993-10-12 The Procter & Gamble Company His-Gly-Gly peptide and derivatives thereof for hair growth
US5280038A (en) 1992-03-13 1994-01-18 Virginia Commonwealth University Histidine as a protective agent in cardiac surgery and myocardial ischemic syndrome
CA2094785A1 (en) 1992-05-08 1993-11-09 Jean Gariepy Metal chelating peptide
US5807535A (en) 1992-07-31 1998-09-15 Australian Nuclear Science & Technology Organisation Metal complexes of hydroxyaryl containing aminocarboxylic acid chelating agents
US5380747A (en) 1992-10-30 1995-01-10 Emory University Treatment for atherosclerosis and other cardiovascular and inflammatory diseases
US5650134A (en) 1993-01-12 1997-07-22 Novartis Ag (Formerly Sandoz Ltd.) Peptides
US5464934A (en) 1993-05-14 1995-11-07 Mallinckrodt Medical, Inc. Metal chelates as spacer compounds in biologically active peptides
US5994339A (en) 1993-10-15 1999-11-30 University Of Alabama At Birmingham Research Foundation Oxidant scavengers
US5476939A (en) 1993-12-30 1995-12-19 Abbott Laboratories Certain pyridyl and isoquinolyl carbinolamine derivatives
JPH07316192A (ja) 1994-05-27 1995-12-05 Hoechst Japan Ltd Ｌ−リシル−グリシル−ｌ−ヒスチジンおよびこれを含有する創傷治療剤
US5538945A (en) 1994-06-17 1996-07-23 Procyte Corporation Stimulation of hair growth by peptide copper complexes
US5891418A (en) 1995-06-07 1999-04-06 Rhomed Incorporated Peptide-metal ion pharmaceutical constructs and applications
EP0955044B1 (en) 1995-06-26 2005-11-16 Chelator LLC Method of inhibiting bacterial or fungal growth using a complexing agent
US5637311A (en) 1995-06-29 1997-06-10 Procyte Corporation Zinc(II) complexes and methods related thereto
RU2106146C1 (ru) 1995-07-17 1998-03-10 Институт элементоорганических соединений РАН Средство для подавления опухолевого роста
US5786335A (en) 1995-11-06 1998-07-28 Warner-Lambert Company Sulfhydryl containing peptides for treating vascular disease
US5928955A (en) 1996-03-22 1999-07-27 California Institute Of Technology Peptidyl fluorescent chemosensor for divalent zinc
WO1997044313A1 (en) 1996-05-21 1997-11-27 Novartis Ag N,N'-Di(2-HYDROXYBENZYL)ETHYLENEDIAMINE-N,N'-DIACETIC ACID DERIVATIVES
GB9613182D0 (en) 1996-06-24 1996-08-28 Nycomed Imaging As Method
PL184070B1 (pl) 1996-07-30 2002-08-30 Politechnika Lodzka Sposób wytwarzania peptydów zawierających a-hydroksymetyloserynę
US5906996A (en) 1996-08-21 1999-05-25 Murphy; Michael A. Tetramine treatment of neurological disorders
US5922761A (en) 1996-09-06 1999-07-13 Medinox, Inc. Methods for in vivo reduction of iron levels and compositions useful therefor
US5739395A (en) 1997-01-10 1998-04-14 University Of Florida Research Foundation, Inc. Method for synthesis of rhizoferrin
GB9711093D0 (en) 1997-05-29 1997-07-23 British Tech Group Novel orally active iron (III) chelators
TR200002256T2 (tr) 1998-02-04 2001-03-21 University Of Florida Research Foundation, Inc. Demir celatlama tedavisinde N,N' -BIS(2-Hidroksibenzil) etilendiamin-N, N'diasetik asit içeren farmasötikler.
DE19819843A1 (de) 1998-05-05 1999-11-11 Biotechnolog Forschung Gmbh Metallchelat bindende Peptide
CA2328457A1 (en) 1998-06-20 1999-12-29 Washington University Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Catherine Harford and Bibudhendra Sarkar.Amino Terminal Cu（II）-and Ni（II）-binding（ATCUN）motif of proteins and peptides：metal binding，DNA cleavage，and other properties.《Acc. Chem. Res.》.1997,第30卷123-130. *
JP昭62-116565A 1987.05.28

Also Published As

Publication number Publication date
KR20120023147A (ko) 2012-03-12
IL148797A (en) 2010-12-30
KR20090086437A (ko) 2009-08-12
ATE553116T1 (de) 2012-04-15
KR20100075503A (ko) 2010-07-02
EP1220870B1 (en) 2012-04-11
IL207923A0 (en) 2011-07-31
KR20120024890A (ko) 2012-03-14
IL148797A0 (en) 2002-09-12
JP2003528814A (ja) 2003-09-30
NZ518266A (en) 2005-01-28
EP1220870A1 (en) 2002-07-10
CA2385551A1 (en) 2001-04-12
CN102038932A (zh) 2011-05-04
KR101062041B1 (ko) 2011-09-02
KR101312880B1 (ko) 2013-09-30
AU7740700A (en) 2001-05-10
KR101353140B1 (ko) 2014-01-20
HK1157635A1 (en) 2012-07-06
AU770999B2 (en) 2004-03-11
IL202812A0 (en) 2011-07-31
EP1220870A4 (en) 2004-04-07
CN1390231A (zh) 2003-01-08
WO2001025265A1 (en) 2001-04-12
KR20110049875A (ko) 2011-05-12
KR20020057966A (ko) 2002-07-12
EP2327713A1 (en) 2011-06-01
JP5349722B2 (ja) 2013-11-20
BR0014389A (pt) 2002-10-29
AU770999C (en) 2005-04-21

Similar Documents

Publication Publication Date Title
US8017728B2 (en) Metal-binding compounds and uses therefor
US7973008B2 (en) Metal-binding compounds and uses therefor
CA2174236C (en) Superoxide dismutase and mimetics thereof
US20030130185A1 (en) Metal-binding compounds and uses therefor
CN102038932B (zh) 金属-结合性化合物及其用途
JP2004535461A (ja) プロテインｃの不活性化を抑制するための銅キレート剤の使用
US8697645B2 (en) Second generation low oxygen affinity pegylated hemoglobins as oxygen-carrying plasma expanders
HK1157635B (en) Metal-binding compounds and uses thereof
HK1158230A (en) Metal-binding compounds and uses therefor
WO2002064620A2 (en) Metal-binding compounds and uses therefor
JP2002060346A (ja) 新規な虚血・再灌流障害抑制剤
HK1051049A (en) Metal-binding compounds and uses thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1157635

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1157635

Country of ref document: HK

ASS Succession or assignment of patent right

Owner name: AMPI'O PHARMACEUTICAL CO., LTD.

Free format text: FORMER OWNER: DMI ACQUISITION CORP.

Effective date: 20140214

Owner name: DMI ACQUISITION CORP.

Free format text: FORMER OWNER: DMI BIOSCIENCES, INC.

Effective date: 20140214

TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20140214

Address after: American Colorado

Patentee after: Ampio Pharmaceuticals, Inc.

Address before: American Colorado

Patentee before: DMI Acquisition Corp.

Effective date of registration: 20140214

Address after: American Colorado

Patentee after: DMI ACQUISITION Corp.

Address before: American Colorado

Patentee before: DMI Biosciences, Inc.

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20131106

Termination date: 20150929

EXPY Termination of patent right or utility model